The Filing Desk

Agios Pharmaceuticals vs Lexicon Pharmaceuticals

Agios Pharmaceuticals AGIO · Lexicon Pharmaceuticals LXRX · Pharmaceuticals

Agios Pharmaceuticals reported revenue of $54 million in fiscal 2025, about the same as Lexicon Pharmaceuticals' $50 million in fiscal 2025. Agios Pharmaceuticals' revenue grew 48.0% in its latest year, and Lexicon Pharmaceuticals' grew 60.2%. Agios Pharmaceuticals had an operating margin of -873.9%, against -98.2% at Lexicon Pharmaceuticals. Free cash flow was −$377 million at Agios Pharmaceuticals and −$68 million at Lexicon Pharmaceuticals.

Side by side

Agios PharmaceuticalsLexicon Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$54M$50M
Revenue growth48.0%60.2%
Revenue growth a year, last 5 years—15.7%
Gross margin88.3%99.5%
Operating margin−873.9%−98.2%
Net margin−764.0%−101.1%
Free cash flow−$377M−$68M
Free cash flow margin−698.3%−136.2%
Return on capital—−105.0%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count0.1%13.4%
Last close$28.76$1.67
P/E at the last close——
Insider trades, last 12 monthssold $4.3 millionbought $2.7 million, sold $0
Piotroski F-score—4 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Agios PharmaceuticalsLexicon Pharmaceuticals
Operating margin
Percent of revenue
Agios PharmaceuticalsLexicon Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Agios PharmaceuticalsLexicon Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Agios Pharmaceuticals and Lexicon Pharmaceuticals pages.